Review
Roles of PTEN with DNA Repair in Parkinson’s Disease

Mako Ogino †, Mayuko Ichimura, Noriko Nakano, Akari Minami, Yasuko Kitagishi † and Satoru Matsuda *
Department of Food Science and Nutrition, Nara Women’s University, Kita-Uoya Nishimachi, Nara 630-8506, Japan; turuchan22@gmail.com (M.O.); of16005@gmail.com (M.I.); okappi0214@yahoo.co.jp (N.N.); maiknaarmii@gmail.com (A.M.); y_kitagishi@live.jp (Y.K.)

* Correspondence: smatsuda@cc.nara-wu.ac.jp; Tel./Fax: +81-742-20-3451
† These authors contributed equally to this work.

Academic Editor: William Chi-shing Cho
Received: 25 April 2016; Accepted: 9 June 2016; Published: 15 June 2016

Abstract: Oxidative stress is considered to play key roles in aging and pathogenesis of many neurodegenerative diseases such as Parkinson’s disease, which could bring DNA damage by cells. The DNA damage may lead to the cell apoptosis, which could contribute to the degeneration of neuronal tissues. Recent evidence suggests that PTEN (phosphatase and tensin homolog on chromosome 10) may be involved in the pathophysiology of the neurodegenerative disorders. Since PTEN expression appears to be one dominant determinant of the neuronal cell death, PTEN should be a potential molecular target of novel therapeutic strategies against Parkinson’s disease. In addition, defects in DNA damage response and DNA repair are often associated with modulation of hormone signaling pathways. Especially, many observations imply a role for estrogen in a regulation of the DNA repair action. In the present review, we have attempted to summarize the function of DNA repair molecules at a viewpoint of the PTEN signaling pathway and the hormone related functional modulation of cells, providing a broad interpretation on the molecular mechanisms for treatment of Parkinson’s disease. Particular attention will be paid to the mechanisms proposed to explain the health effects of food ingredients against Parkinson’s disease related to reduce oxidative stress for an efficient therapeutic intervention.

Keywords: oxidative stress; ROS; DNA repair; PTEN; BRCA1; estrogen; Parkinson’s disease

1. Introduction

DNA damage and mitochondrial dysfunction may constitute a common pathway to neurodegenerative disorders [1,2]. However, initial underlying mechanisms that trigger the neurodegeneration in Parkinson’s disease (PD) are complex. PD is caused by the degeneration of dopaminergic neurons of the substantia nigra, which are required for proper motor function, and their loss is associated with tremor, bradykinesia, rigidity, and so on [3,4]. Dysfunction of mitochondria is thought to play an essential role in the neurodegeneration of the substantia nigra in brain, but the mechanisms involved remain unresolved. High levels of reactive oxygen species (ROS) are widely considered as a key event in the pathogenesis of PD, which is an intrinsic property of the vulnerable ventral midbrain dopaminergic neurons [5,6]. PD patients would worsen over time and suffer from considerable cognitive disability. To date, treatments are only symptomatic. Because mitochondria contain a number of enzymes essential for redox homeostasis, even a subtle defect in oxidative stress may cause not only fatal failure in neurons but also generates a large amount of ROS toxic to the vulnerable neurons in the central nervous system. Therefore, defective mitochondrial physiology may play a crucial role in the pathogenesis of PD. DNA damage and repair after the oxidative stress should
activate the enzyme ataxia telangiectasia mutated (ATM) that is one of a cell cycle regulators [7,8]. Under stress conditions, those checkpoint proteins may play the key roles in genome protection by and mediating cellular response to DNA damage, and represent an important part of cellular stress response. A major focus of neuroscience research is to examine the precise mechanisms involved in the neuronal loss in order to find potential therapeutic targets [9–11]. Advances in a field of DNA damage and DNA repair biology have led to a better understanding of the molecular events significant in the pathogenesis of PD, and the understanding of the mitochondrial regulating pathways has raised several promising perspectives of neuroprotection. The knowledge of the mechanisms involved in the intracellular signaling cascades and molecular mechanisms which accomplish the process of DNA damage and DNA repair for neuroprotection could be critical for developing treatments to prevent and improve PD, other neurodegenerative disorders, and even aging to control the excess progression.

2. DNA Damage and DNA Repair in Neurodegeneration

Oxidative damage is commonly involved in brain aging, neurodegeneration, and other neurological diseases, which can be created by usual cellular metabolism. Metabolic process produces ROS that accounts for oxidative damage to genome DNA [12,13]. In fact, increased oxidative DNA damage has been detected in nuclear and mitochondrial DNAs extracted from brain region of patients affected by neurodegenerative disorders [14–16]. Besides, neurodegenerative diseases are often associated with premature aging [17,18]. Oxidative DNA damage is one of the earliest detectable events in the neurodegeneration [19]. Convincing evidence has shown that oxidative DNA damage plays a central role in a programmed neuronal cell death, and is considered to be responsible for the degeneration of the dopaminergic neurons in PD [20]. However, machineries underlying the oxidative damage-mediated loss of the specific dopaminergic neurons in PD are not yet fully clarified. DNA damage is well-defined as a modification that changes its coding stuffs, and many different forms of DNA damage can be produced by both exogenous oxidative stressors and normal cellular functions. The process may involve a quantity of signaling cascades and molecules. High levels of mitochondrial genome mutations have been identified in dopaminergic neurons in the substantia nigra of neurodegenerative disease-patients relative to normal healthy controls [21,22], which has raised a speculation for an underlying connection between mitochondrial mutations and the neurodegeneration [21,22]. DNA damage is different from simple DNA mutations, which are alterations in base sequences of DNA. Generally, brain cells have an extraordinary level of metabolic activity and use discrete oxidative damage-repair mechanisms to remove the unacceptable many damages [23,24]. Hence, defective DNA repair system in brain cells could contribute to the neurological dysfunction. Standard cells have a machinery to maintain genomic integrity in response to the numerous genotoxic events. Under the genotoxic conditions, the cells do not move cell-cycle by activating the specific checkpoint in DNA damage [25–28] that acts as a procedure to transduce information from damaged DNA lesions to the cell-cycle regulator molecules. Then, DNA lesions can be repaired by DNA repair pathway. Initially, DNA damages accumulate with acute cellular stress conditions, which activate ATM, ataxia telangiectasia and Rad3 related (ATR), E2F, BRCA1, transcription factor and so on. In addition, pathways that have appeared as having crucial roles in both neurodegenerative diseases and cancer include those involving molecules such as ATM and PTEN [29] (Figure 1). Schematic structure of the predicted PTEN, ATM and BRCA1 is shown in Figure 2. Consequently, DNA damage induces G2/M arrest, which is a result from the activation of the ATM followed by the activation of Chk [30,31]. Aberrations of these molecules are frequently found in patients with neurodegenerative diseases [32]. In general, normal cells show a balance of the various mechanisms of the DNA damage and DNA repair machinery. Linking DNA damage and DNA repair with cell cycle inhibitors involving epigenetic regulatory phenomena might open the way to an attractive research topic in neurodegenerative diseases [16,33].
Figure 1. Schematic depiction of the integrative model of tumor suppressors signaling including PTEN and BRCA1 and implication of estrogen action, DNA damage, and DNA repair systems. Typical molecules known to act on DNA damage response, cell proliferation, and cell cycle via the regulatory pathways are shown. Arrowhead means stimulation whereas hammerhead represents inhibition. Note that some critical pathways have been omitted for clarity.

Figure 2. Schematic diagram indicating the domain structures of the PTEN, ERα, BRCA1, and ATM proteins. Note that the sizes of molecule are modified for clarity. PH domain = pleckstrin homology domain; C2 domain = a protein structural domain involved in targeting proteins to cell membranes; PDZ = a common structural domain in signaling proteins (PSD95, Dlg, ZO-1, etc.); AF1 = activation function 1; DBD = DNA-binding domain; LBD = ligand-binding domain; Ring = (Really Interesting New Gene) finger domain; NLS = Nuclear Localization Signal; BRCT = BRCA1 C Terminus; HEAT = huntington, elongation factor 3, a subunit of PP2A and TOR1; FAT = FRAP-ATM-TRRAP; FATC = FAT-C-terminal.
3. Association between PTEN and DNA Damage/DNA Repair Machinery in Neurodegenerative Diseases

Phosphatase and tensin homolog on chromosome 10 (PTEN) is a dual-specificity phosphatase acting as a tumor suppressor, which has both protein phosphatase activity and lipid phosphatase activity that upsets PI3K activity [34,35]. The PI3K/AKT pathway transduces a signal regulating a wide range of events involved in cell survival and several functions (Figure 1). Cells without PTEN have constitutively upper levels of PIP3 and activate downstream PI3K/AKT targets [36,37]. Overexpression of PTEN may be closely related to the activation of the proteolytic cascade for apoptosis, which can be correlated with decreased activation of cell survival kinase AKT [38]. Accordingly, neuronal cell death may be attributed in part to the alterations in PTEN expression [39,40]. Regulation of apoptosis has been concerned in the pathogenesis of numerous neurodegenerative disorders. Therefore, it is important to identify neuronal pathways controlling apoptosis. Stimulation of AKT reduces oxidative stress levels and cell death, indicating that AKT activation by inactivation of PTEN is important to reserve its neuro-protective effect [41–43], which may construct a part of brain defense machinery against oxidative injury [41–43]. It has been shown PTEN insufficiency results in the increase of several mitochondrial activities, along with an activation of the PI3K/AKT signaling pathway, of which PTEN may be a negative regulator [44]. In addition, a ubiquitously expressed molecule PTEN-induced kinase 1 (PINK1) has been shown to have a physiological role in mitochondrial conservation, suppressing mitochondrial oxidative stress, oxidative DNA damage, and autophagy [45,46]. PINK1 knockdown increases the neuronal apoptosis, whereas PINK1 overexpression returns it [47–49]. PINK1 plays crucial roles in the regulation of mitochondrial function and dynamics, and mutations in PINK1 have been linked to genetic forms of PD [50]. Protective role of PINK1 in neuronal cells against oxidative stress has also been suggested for developing novel strategy to the treatment of neurodegenerative diseases. It has been shown that NADPH oxidase-mediated ROS production elicits oxidation and inactivation of PTEN resulting in upregulation of the signaling [51]. Similarly, PTEN is oxidized and inactivated by the acidosis-induced ROS [52]. Inhibition of PTEN by ROS is needed for recruiting downstream signaling molecules such as AKT in insulin-mediated signaling [53]. The major form of oxidative DNA damage base in the DNA is 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG). Arsenite-induced oxidation increases the 8-oxodG and decreases PTEN levels [54]. However, how PINK1 is involved in the neuronal cell survival against oxidative stress and damage remains not precisely clarified.

As mentioned above, main DNA damage recognition molecule is ATM, which is a cell-cycle checkpoint kinase that phosphorylates a number of proteins including p53 and BRCA1 in response to DNA damage (Figure 2), and thus induces the response to DNA damage [32,55]. PTEN plays a role in G2/M arrest by facilitating the activation of the ATM (Figure 2) pathway required for the proper activation of checkpoints in response to DNA damages. In addition, PTEN has serious roles in the regulation of genomic instability and DNA repair pathways [56,57]. Knockdown of PTEN strongly antagonizes the ATM activation and thereby reduces the phosphorylation level of ATM-substrates including Chk, H2AX, and p53 [58,59]. Recent studies have shown that PTEN plays distinctive roles in the DNA damage response and can interact with the Chk pathway [59]. Formation of phospho-H2AX is an integral part of the signaling pathway for double strand break repairs in which PTEN may be involved [60,61]. Genomic instability eventually induces cell death and/or apoptosis [62]. However, little is known about how PTEN contributes to DNA damage responses. BRCA1 is a well-known breast cancer tumor suppressor, which is to associate with breast cancer risk and genetic susceptibility [63]. Several studies have revealed that BRCA1as well as PTEN plays a critical role in DNA damage responses. The PI3K/AKT pathway is constitutively active in BRCA1-defective cells [64]. PTEN has been shown to trans-activate RAD51 promoter with a member of the E2F transcription molecule family [65]. Since the E2F complexes associate with histone modifying enzymes, histone modifications together with its acetylation and methylation are required for cell cycle regulation in DNA repair system. Furthermore, PTEN is a target of nitric oxide (NO) and/or hydrogen peroxide, and the oxidative modification of cysteine residue diminishes its enzymatic activity [66]. Phosphatase activity...
of PTEN is inhibited via the transnitrosylation reaction such as a transfer of NO from the cysteine residue of a protein to another site [67]. PTEN has been shown sensitive to NO under the conditions. Detoxification of ROS and/or reduction of ROS could protect neurons. Importantly, nitrosylation of PTEN decreases the phosphatase activity of PTEN, thus in consequence activating PI3K/AKT, and then promoting cell survival.

4. Estrogen and Its Receptor Signaling with PTEN Involved in PD

Numbers of genetic researches suggest that the pathogenesis of PD and cancer may include similar mechanisms and pathways [68]. Actually, PTEN is a famous tumor suppressor that is functionally associated with numerous human cancers. PTEN and BRCA1 are recognized as often deleted and/or mutated genes in several human cancers. The BRCA1 molecule functionally cooperates with PTEN and might be an indispensable blockage against the development of several tumors [36]. PD is initiated by the specific degeneration of dopaminergic neurons, whereas cancer results from the immoral growth of malignant cells. Differences in the pathological and intracellular signaling mechanisms may result in two such divergent diseases. Recent studies have informed a relationship between DNA repair deficiency and loss of sex hormone signaling [69,70]. Estrogens are primary female sex hormones and play important roles in the reproductive systems, which can be synthesized even in non-reproductive tissues such as heart, liver, brain, muscle, and bone. Estrogens not only show a fundamental role in cell proliferation and differentiation on several epithelia but also are involved in control diverse cellular processes. Tissue-specific synthesis may be consistent with a variety of the estrogen actions. Interestingly, studies have shown that mitochondria are an imperative target of estrogen [71,72]. Estrogen augments mitochondrial role by enhancing mitochondrial biogenesis and supporting mitochondrial capacity. Hence, estrogen has been suggested as a possible therapeutic mediator against neurodegeneration due to the strong anti-oxidant and anti-apoptotic properties. Estrogens also induce the expression of genes such as BRCA1 that can act to repair the DNA damage. Contemporary studies have shown an association between DNA repair deficiency and loss of specific estrogen receptors (ERs) [16] (Figure 2). In addition, two major ERs-dependent signaling seems to be involved in the neuroprotective roles against PD [73,74]. In PD experimental animal model, estrogen-treatment protects against neuronal cell death, and an inhibitor of the PI3K/AKT pathway blocks the survival effects of estrogen to dopamine neurons. Estrogen may mediate neuroprotection through the inactivation of PTEN activity and/or decrease in PTEN expression level [75,76], which may be used as a key parameter for evaluation of the efficacy of estrogen in prevention of neuronal degeneration. In contrast, estrogen-related receptor α is up-regulated in the absence of PTEN [77]. PI3K/AKT activity also regulates the expression of estrogen-related receptor α and mitochondrial respiration [77]. Therefore, estrogen may be an effective novel treatment approach to inhibit the neuronal cell death. Foods such as soy and beans are sources of phyto-estrogens. The phyto-estrogens have direct effects on differential mediators of the mitochondrialogenesis procedure [78].

Mitochondrial dysfunction has been reported in most neurodegenerative diseases. Specific deletion of PTEN and/or estrogen receptors is associated with high oxidative stress, increased mitochondrial form and augmented respiration [77]. In addition to the specific deletions, some other mechanisms might change the activities of PTEN and/or estrogen receptors. For example, PTEN inactivation is caused by somatic mutations, inherited germline mutations, epigenetic silencing, post-translational modifications, and molecular interactions [79]. Epigenetic mechanisms such as histone modifications, DNA methylation, and small RNA-mediated mechanisms, could regulate the expression of PD-related genes including PTEN [80]. Accordingly, linking DNA damage and DNA repair with epigenetic phenomena opens the way to an attractive research topic in neurodegenerative diseases [16]. A low PTEN expression due to the methylation may also contribute to malignant cancer progression and could be useful for the prognosis [81]. Particular attention should be paid to the molecular mechanisms suggested to explain the cellular wellbeing-effects such as neuroprotection.
against the diseases related to oxidative stress driven pathologies including neurodegenerative disease and/or PD (Figure 3). Indeed, the knowledge of mechanisms involved in this cellular protection could be critical for developing treatments to prevent the neurodegenerative disorders to control its excess progression.

![Figure 3. Schematic representation of the DNA repair system for neuroprotection implying that genome stability is sustained on several tumor suppressors. Examples of the action known to act on the neuron survival pathways are shown. Several dietary modulators linked to this pathway are also demonstrated, whose potential molecular targets may be based on the predominant sites. Note that some critical functions have been omitted for clarity.](image)

5. Diets May Contribute to the Improved Neuron-Survival via the Modulation of PI3K/AKT/PTEN Signaling

Effective therapeutic strategies should exploit the remark that defects in significant processes required for cellular homeostasis, which produce an alternative functional situation (Figure 3). Dietary interventions to reduce PTEN expression could contribute to the prevention of the neurodegenerative diseases and/or decrease the speed of its progress. Lately, omega-3 (n-3) long-chain polyunsaturated fatty acids (PUFAs) have become an attention of interest in neurology [82]. Particularly, docosahexaenonic acids (DHA) are important for brain development and neuronal health [83]. Consequently, fish oil administration may retain hippocampal neurons and recovers cognitive deficit by activation of PI3K/AKT signaling [84]. Fish oil diet modifies the level of PTEN protein [85]. In this way, neuroprotection could be performed by certain diets involved in the PI3K/AKT/PTEN pathway. Curcumin, an active ingredient derived from the root of the plant *Curcuma longa* widely used as culinary spice turmeric, can improve plasticity of synapse, which then enhances memory abilities [86,87]. It is proposed that the neuroprotection of curcumin might be facilitated via the alteration of PI3K/AKT activity [88,89]. Several plants or fruits may also be favorable. Kaempferol is a flavonol that is present in various plants including some edible berries and grapefruits, which has neuroprotective effects in the mouse model of PD [90]. In addition, some component of rosemary herb inhibits the PTEN expression in K562 myeloid cell line cells [91]. Icariin is a neuroprotective ingredient of *Herba Epimedii*, a traditional Chinese medicinal herb, which also inhibits the PTEN expression following AKT activation [92–94]. Taurine, a sulfur-containing amino acid located in mammalian tissues in high concentrations, possesses
a variety of biological actions, such as ion movement, antioxidant capacity, osmoregulation and mitochondrial function [95]. AKT and PTEN phosphorylation is significantly increased by taurine supplementation, resulting PTEN inactivation and AKT activation [96]. In addition, a high-fat diet increases circulating fatty acids, which considerably modifies the PTEN expression [97].

On the contrary, Honokiol, an active component isolated and purified from Chinese traditional herb magnolia, may be able to decrease the PI3K/AKT signaling by upregulation of the PTEN expression [98]. Soy isoflavones at physiologically relevant concentrations by dietary exposure also stimulates PTEN expression [99]. In addition, genistein, a major isoflavone found in soybeans upregulates PTEN expression [100]. Both quercetin and genistein have an influence to up-regulate PTEN transcription, then, suppresses the PI3K/AKT signaling pathway. Generally, phytoestrogen exposure may cause a transcriptional increase in PTEN expression. Biological activity of the isothiocyanates, rich in certain vegetables such as broccoli, has been demonstrated to suppress AKT signaling [101]. Indole-3-carbinol, a phytochemical found in certain vegetables, upregulates PTEN in experimental animal model [102,103]. Interestingly, animals with tryptophan-restriction show a reduced activity of phosphorylated AKT [104]. However, in spite of these experimental interpretations, the accurate mechanisms for those food ingredients remain obscure for clinical practices. Furthermore, it seems imperative to exploit the potential profits of optimal treatment and/or combination with chemical modulators on PI3K/AKT pathway.

6. Perspective

There is an imperative requisite to recognize more about DNA repair pathways. The DNA repair system is an extremely conserved DNA excision process that keeps genomic fidelity through the credit and repair of the damaged nucleotides. Because apoptotic cell death is demonstrative of neurodegeneration, down-regulation of PTEN may be required to prevent the progression of neurodegenerative disorders. In addition, signaling pathway of several hormones has a complex network, and thus further comprehensive research in this area is mandatory for investigation. Detection of the other molecular pathways would be supportive to better understand the essential mechanisms of hormone dependence to the neuroprotection. It is plausible that certain food ingredients including phytoestrogens act as antioxidants by scavenging ROS to protect certain neurons from DNA damage via the modulation of PI3K/AKT pathway. Further systematic studies are needed in order to realize the precise molecular mechanisms of hormonal and PTEN involved DNA repair scheme for effective prevention and therapeutic intrusions of PD.

Acknowledgments: This work was supported by JSPS KAKENHI Grant Numbers 25560050, 26-12035, and 24240098.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Acronym | Definition |
|---------|------------|
| ATM     | ataxia telangiectasia mutated |
| ATR     | ataxia telangiectasia and Rad3 related |
| BRCA1   | breast cancer susceptibility gene 1 |
| DHA     | docosahexaenoic acid |
| ER      | estrogen receptor |
| n-3 PUFA| omega-3 polyunsaturated fatty acid |
| NO      | nitric oxide |
| 8-oxodG | 8-oxo-7,8-dihydro-2′-deoxyguanosine |
| PD      | Parkinson’s disease |
| PI3K    | Phosphoinositide 3-kinase |
| PINK1   | PTEN-induced kinase 1 |
| PTEN    | phosphatase and tensin homolog on chromosome 10 |
| PUFAs   | polyunsaturated fatty acids |
| ROS     | reactive oxygen species |
References

1. Folch, J.; Junyent, F.; Verdaguer, E.; Auladell, C.; Pizarro, J.G.; Beas-Zarate, C.; Pallás, M.; Camins, A. Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death. *Neurotox. Res.** 2012, 22, 195–207. [CrossRef] [PubMed]

2. Arun, S.; Liu, L.; Donmez, G. Mitochondrial biology and neurological diseases. *Curr. Neuropharmacol.** 2016, 14, 143–154. [CrossRef] [PubMed]

3. Beitz, J.M. Parkinson's disease: a review. *Front. Biosci.** 2014, 6, 65–74. [CrossRef]

4. Martin, H.L.; Teismann, P. Glutathione—a review on its role and significance in Parkinson's disease. *FASEB J.** 2009, 23, 3263–3272. [CrossRef] [PubMed]

5. Tansey, M.G.; Goldberg, M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. *Neurobiol. Dis.** 2010, 37, 510–518. [CrossRef] [PubMed]

6. Collins, M.A.; Neafsey, E.J. Potential neurotoxic "agents provocateurs" in Parkinson's disease. *Neurotoxicol. Teratol.** 2002, 24, 571–577. [CrossRef]

7. Castillo, P.; Bogliolo, M.; Surrellas, J. Coordinated action of the Fanconi anemia and ataxia telangiectasia pathways in response to oxidative damage. *DNA Repair** 2011, 10, 518–525. [CrossRef] [PubMed]

8. Ma, Y.; Lu, H.; Schwarz, K.; Lieber, M.R. Repair of double-strand DNA breaks by the human nonhomologous DNA end joining pathway: the iterative processing model. *Cell Cycle** 2005, 4, 1193–1200. [CrossRef] [PubMed]

9. Benskey, M.J.; Perez, R.G.; Manfredsson, F.P. The contribution of alpha synuclein to neuronal survival and function-implications for Parkinson's disease. *J. Neurochem.** 2016, 137, 331–359. [CrossRef] [PubMed]

10. Cacabelos, R.; Alvarez, A.; Lombardi, V.; Fernández-Novoa, L.; Corzo, L.; Pérez, P.; Laredo, M.; Pichel, V.; Hernández, A.; Varela, M.; et al. Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. *Drugs Today** 2000, 36, 415–499. [PubMed]

11. Hoque, A.; Hossain, M.I.; Ameen, S.S.; Ang, C.S.; Williamson, N.; Ng, D.C.; Chueh, A.C.; Roulston, C.; Cheng, H.C. A beacon of hope in stroke therapy-blockade of pathologically activated cellular events in excitotoxic neuronal death as potential neuroprotective strategies. *Pharmacol. Ther.** 2016, 160, 159–179. [CrossRef] [PubMed]

12. Anuranjani; Bala, M. Concerted action of Nrf2-ARE pathway, MRN complex, HMGB1 and inflammatory cytokines - implication in modification of radiation damage. *Redox Biol.** 2014, 2, 832–846. [CrossRef] [PubMed]

13. Bagchi, D.; Stohs, S.J.; Downs, B.W.; Bagchi, M.; Preuss, H.G. Cytotoxicity and oxidative mechanisms of different forms of chromium. *Toxicology** 2002, 180, 5–22. [CrossRef]

14. Zhang, J.; Perry, G.; Smith, M.A.; Robertson, D.; Olson, S.J.; Graham, D.G.; Montine, T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. *Am. J. Pathol.** 1999, 154, 1423–1429. [CrossRef]

15. Wang, J.; Markesbery, W.R.; Lovell, M.A. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. *J. Neurochem.** 2006, 96, 825–832. [CrossRef] [PubMed]

16. Coppedè, F.; Migliore, L. DNA damage in neurodegenerative diseases. *Mutat. Res.** 2015, 776, 84–97. [CrossRef] [PubMed]

17. Bagchi, D.; Stohs, S.J.; Downs, B.W.; Bagchi, M.; Preuss, H.G. Cytotoxicity and oxidative mechanisms of different forms of chromium. *Toxicology** 2002, 180, 5–22. [CrossRef] [PubMed]

18. Rass, U.; Abel, I.; West, S.C. Defective DNA repair and neurodegenerative disease. *Cell** 2007, 130, 991–1004. [CrossRef] [PubMed]

19. Coppedè, F.; Migliore, L. DNA damage and repair in Alzheimer's disease. *Curr. Alzheimer Res.** 2009, 6, 36–47. [CrossRef] [PubMed]

20. Li, D.W.; Li, G.R.; Zhang, B.L.; Feng, J.J.; Zhao, H. Damage to dopaminergic neurons is mediated by proliferating cell nuclear antigen through the p53 pathway under conditions of oxidative stress in a cell model of Parkinson's disease. *Int. J. Mol. Med.** 2016, 37, 429–435. [CrossRef] [PubMed]

21. Van der Merwe, C.; Loos, B.; Swart, C.; Kinnear, C.; Henning, F.; van der Merwe, L.; Pillay, K.; Muller, N.; Zaharie, D.; Engelbrecht, L.; et al. Mitochondrial impairment observed in fibroblasts from South African Parkinson's disease patients with parkin mutations. *Biochem. Biophys. Res. Commun.** 2014, 447, 334–340. [CrossRef] [PubMed]
22. Bender, A.; Schwarzkopf, R.M.; McMillan, A.; Krishnan, K.J.; Rieder, G.; Neumann, M.; Elstner, M.; Turnbull, D.M.; Klopf Stock, T. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. *J. Neurol.* 2008, 255, 1231–1235. [CrossRef] [PubMed]

23. Canugovi, C.; Misiak, M.; Ferrarelli, L.K.; Croteau, D.L.; Bohr, V.A. The role of DNA repair in brain related disease pathology. *DNA Repair* 2013, 12, 578–587. [CrossRef] [PubMed]

24. Biancotti, J.C.; Kumar, S.; de Vellis, J. Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair. *Neurochem. Res.* 2008, 33, 2615–2628. [CrossRef] [PubMed]

25. Dong, J.; Wang, Z.; Zou, P.; Zhang, G.; Dong, X.; Ling, X.; Zhang, X.; Liu, J.; Ye, D.; Cao, J.; et al. Induction of DNA damage and G2 cell cycle arrest by diepoxynitrate through the activation of the Chk1-dependent pathway in mouse germ cells. *Chem. Res. Toxicol.* 2015, 28, 518–531. [CrossRef] [PubMed]

26. Paiva, C.; Godbersen, J.C.; Berger, A.; Brown, J.R.; Danilov, A.V. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents. *Cell Death Dis.* 2015, 6, e1807. [CrossRef] [PubMed]

27. Mahajan, K.; Mahajan, N.P. Cross talk of tyrosine kinases with the DNA damage signaling pathways. *Nucleic Acids Res.* 2015, 43, 10588–10601. [CrossRef] [PubMed]

28. Zhang, N.; Huang, L.; Tian, J.; Chen, X.; Ke, F.; Zheng, M.; Xu, J.; Wu, L. A novel synthetic novobiocin analog, FM-Nov17, induces DNA damage in CML cells through generation of reactive oxygen species. *Pharmacol. Rep.* 2016, 68, 423–428. [CrossRef] [PubMed]

29. Morris, L.G.; Veeriah, S.; Chan, T.A. Genetic determinants at the interface of cancer and neurodegenerative disease. *Oncogene* 2010, 29, 3453–3464. [CrossRef] [PubMed]

30. Brozovic, A.; Damrot, J.; Tsaryk, R.; Helbig, L.; Nikolova, T.; Hartig, C.; Osmak, M.; Coos, W.P.; Kaina, B.; Fritz, G. Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response. *Mutat. Res.* 2009, 670, 32–41. [CrossRef] [PubMed]

31. Tomimatsu, N.; Mukherjee, B.; Burma, S. Distinct roles of ATR and DNA-PKcs in triggering DNA damage responses in ATM-deficient cells. *EMBO Rep.* 2009, 10, 629–635. [CrossRef] [PubMed]

32. Motoyama, N.; Naka, K. DNA damage tumor suppressor genes and genomic instability. *Curr. Opin. Genet. Dev.* 2004, 14, 11–16. [CrossRef] [PubMed]

33. Shelton, B.P.; Misso, N.L.; Shaw, O.M.; Arthaningtyas, E.; Bhoola, K.D. Epigenetic regulation of human epithelial cell cancers. *Curr. Opin. Mol. Ther.* 2008, 10, 568–578. [PubMed]

34. Haas-Kogan, D.; Stokoe, D. PTEN in brain tumors. *Expert Rev. Neurother.* 2008, 8, 599–610. [CrossRef] [PubMed]

35. Ruan, H.; Li, J.; Ren, S.; Gao, J.; Li, G.; Kim, R.; Wu, H.; Wang, Y. Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. *J. Mol. Cell. Cardiol.* 2009, 46, 193–200. [CrossRef] [PubMed]

36. Minami, A.; Nakanishi, A.; Ogura, Y.; Kitagishi, Y.; Matsuda, S. Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair. *Front. Oncol.* 2014, 4, 318. [CrossRef] [PubMed]

37. Carnero, A.; Blanco-Aparicio, C.; Renner, O.; Link, W.; Leal, J.F. The PTEN/P13K/AKT signalling pathway in cancer, therapeutic implications. *Curr. Cancer Drug Targets* 2008, 8, 187–198. [CrossRef] [PubMed]

38. Wen, S.; Stolarov, J.; Myers, M.P.; Su, J.D.; Wigler, M.H.; Tonks, N.K.; Durden, D.L. PTEN controls tumor-induced angiogenesis. *Proc. Natl. Acad. Sci. USA* 2001, 98, 4622–4627. [CrossRef] [PubMed]

39. Gary, D.S.; Mattson, M.P. PTEN regulates Akt kinase activity in hippocampal neurons and increases their sensitivity to glutamate and apoptosis. *Neuromol. Med.* 2002, 2, 261–269. [CrossRef]

40. Kyrlyenko, S.; Roschier, M.; Korhonen, P.; Salminen, A. Regulation of PTEN expression in neuronal apoptosis. *Brain Res. Mol. Brain Res.* 1999, 73, 198–202. [CrossRef]

41. Salinas, M.; Martin, D.; Alvarez, A.; Cuadrado, A. Akt1/PKBalpha protects PC12 cells against the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium and reduces the levels of oxygen-free radicals. *Mol. Cell. Neurosci.* 2001, 17, 67–77. [CrossRef] [PubMed]

42. Fan, G.C.; Zhou, X.; Wang, X.; Song, G.; Qian, J.; Nicolaou, P.; Chen, G.; Ren, X.; Kranias, E.G. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity. *Circ. Res.* 2008, 103, 1270–1279. [CrossRef] [PubMed]
43. Dávila, D.; Fernández, S.; Torres-Alemán, I. Astrocyte Resilience to Oxidative Stress Induced by Insulin-like Growth Factor I (IGF-I) Involves Preserved AKT (Protein Kinase B) Activity. J. Biol. Chem. 2016, 291, 2510–2523. [CrossRef] [PubMed]

44. Napoli, E.; Ross-Inta, C.; Wong, S.; Hung, C.; Fusajima, Y.; Sakaguchi, D.; Angelastro, J.; Omanska-Klusek, A.; Schoenfeld, R.; Giulivi, C. Mitochondrial dysfunction in Pten haplo-insufficient mice with social deficits and repetitive behavior: interplay between Pten and p53. PLoS ONE 2012, 7, e42504. [CrossRef] [PubMed]

45. Devireddy, S.; Liu, A.; Lampe, T.; Hollenbeck, P.J. The Organization of Mitochondrial Quality Control and Life Cycle in the Nervous System in Vivo in the Absence of PINK1. Front. Neurosci. 2015, 35, 9391–9401. [CrossRef] [PubMed]

46. Li, L.; Hu, G.K. Pink1 protects cortical neurons from thapsigargin-induced oxidative stress and neuronal apoptosis. Biosci. Rep. 2015, 35, e00174. [CrossRef] [PubMed]

47. Oliveras-Salvá, M.; Machci, F.; Coessens, V.; Deleersnijder, A.; Gérard, M.; Van der Perren, A.; van den Haute, C.; Baekelandt, V. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice. Neurobiol. Aging 2014, 35, 2625–2636. [CrossRef] [PubMed]

48. Burbulla, L.F.; Fitzgerald, J.C.; Stegen, K.; Westermeier, J.; Thost, A.K.; Kato, H.; Mokranjac, D.; Sauerwald, J.; Martins, L.M.; Wotilda, D.; et al. Mitochondrial proteolytic stress induced by loss of mortalin function is rescued by Parkin and PINK1. Cell Death Dis. 2014, 5, e1180. [CrossRef] [PubMed]

49. Büeler, H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease. Exp. Neurol. 2009, 218, 235–246. [CrossRef] [PubMed]

50. Gupta, S.C.; Singh, R.; Pochampally, R.; Watabe, K.; Mo, Y.Y. Acidosis promotes invasiveness of breast cancer cells through ROS-AKT-NF-κB pathway. Oncotarget 2014, 5, 12070–12082. [CrossRef] [PubMed]

51. Kwak, H.J.; Liu, P.; Bajrami, B.; Yu, Y.; Park, S.Y.; Nombela-Arrieta, C.; Mondal, S.; Sun, Y.; Zhu, H.; Chai, L.; et al. Myeloid cell-derived reactive oxygen species externally regulate the proliferation of myeloid progenitors in emergency granulopoiesis. Immunity 2015, 42, 159–171. [CrossRef] [PubMed]

52. Caldon, C.E. Estrogen signaling and the DNA damage response in hormone dependent breast cancers. Front. Oncol. 2014, 4, 106. [CrossRef] [PubMed]

53. Ho, J.; Bassi, C.; Stambolic, V. Characterization of nuclear PTEN and its post translational modifications. Methods 2015, 104–111. [CrossRef] [PubMed]

54. Huang, Y.C.; Yu, H.S.; Chai, C.Y. Roles of oxidative stress and the ERK1/2, PTEN and p70S6K signaling pathways in arsenite-induced autophagy. Toxicol. Lett. 2015, 239, 172–181. [CrossRef] [PubMed]

55. Wang, X.; Huang, H.; Young, K.H. The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Mol. Biol. Cell 2005, 16, 348–357. [CrossRef] [PubMed]

56. Wang, X.; Young, K.H. The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging 2015, 7, 1032–1049. [CrossRef] [PubMed]

57. Ho, J.; Bassi, C.; Stambolic, V. Characterization of nuclear PTEN and its post translational modifications. Methods 2015, 104–111. [CrossRef] [PubMed]

58. Lin, C.T.; Lai, H.C.; Lee, H.Y.; Lin, W.H.; Chang, C.C.; Chu, T.Y.; Lin, Y.W.; Lee, K.D.; Yu, M.H. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci. 2008, 99, 1218–1226. [CrossRef] [PubMed]

59. Zhang, R.; Zhu, L.; Zhang, L.; Xu, A.; Li, Z.; Xu, Y.; He, P.; Wu, M.; Wei, F.; Wang, C. PTEN enhances G2/M arrest in etoposide-treated MCF-7 cells through activation of the ATM pathway. Oncol. Rep. 2016, 35, 2707–2714. [CrossRef] [PubMed]

60. Colis, L.C.; Hegon, D.C.; Kaneko, M.; Glazer, P.M.; Herzon, S.B. Mechanism of action studies of lomaiviticin A and the monomeric lomaiviticin aglycon. Selective and potent activity toward DNA double-strand break repair-deficient cell lines. J. Am. Chem. Soc. 2015, 137, 5741–5747. [CrossRef] [PubMed]

61. Ellis, L.; Ku, S.Y.; Ramakrishnan, S.; Lasorsa, E.; Azadafarzi, G.; Godoy, A.; Pili, R. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. Oncotarget 2013, 4, 2225–2236. [CrossRef] [PubMed]

62. Machamer, C.E. The Golgi complex in stress and death. Front. Neurosci. 2015, 9, 421. [CrossRef] [PubMed]
63. Drooger, J.C.; Hooning, M.J.; Seynaeve, C.M.; Baaijens, M.H.; Obdeijn, I.M.; Sleijfer, S.; Jager, A. Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature. *Cancer Treat. Res.* 2015, 41, 187–196. [CrossRef] [PubMed]

64. Yi, Y.W.; Kang, H.J.; Kim, H.J.; Hwang, J.S.; Wang, A.; Bae, I. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. *Mol. Carcinog.* 2013, 52, 667–675. [CrossRef] [PubMed]

65. Shen, W.H.; Balajee, A.S.; Wang, J.; Wu, H.; Eng, C.; Pandolfi, P.P.; Yin, Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. *Cell* 2007, 128, 157–170. [CrossRef] [PubMed]

66. Ohno, K.; Okuda, K.; Uehara, T. Endogenous S-sulfhydration of PTEN helps protect against modification by nitric oxide. *Biochim. Biophys. Res. Commun.* 2015, 456, 245–249. [CrossRef] [PubMed]

67. Choi, M.S.; Nakamura, T.; Cho, S.J.; Han, X.; Holland, E.A.; Qu, J.; Petsko, G.A.; Yates, J.R.; Liddington, R.C.; Lipton, S.A. Transnitrosylation from DJ-1 to PTEN attenuates neuronal cell death in parkinson’s disease models. *J. Neurosci.* 2014, 34, 15123–15131. [CrossRef] [PubMed]

68. Li, Z.; Lin, Q.; Ma, Q.; Lu, C.; Tseng, C.M. Genetic predisposition to Parkinson’s disease and cancer. *Curr. Cancer Drug Targets* 2014, 14, 310–321. [CrossRef] [PubMed]

69. Pérez-Sieira, S.; López, M.; Nogueiras, R.; Tovar, S. Regulation of NR4A by nutritional status, gender, postnatal development and hormonal deficiency. *Sci. Rep.* 2014, 4, 4264. [CrossRef] [PubMed]

70. Savage, K.I.; Matchett, K.B.; Barros, E.M.; Cooper, K.M.; Irwin, G.W.; Gorski, J.J.; Orr, K.S.; Vohhodina, J.; Drooger, J.C.; Hooning, M.J.; Seynaeve, C.M.; Baaijens, M.H.; Obdeijn, I.M.; Sleijfer, S.; Jager, A. Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature. *Cancer Treat. Res.* 2015, 41, 187–196. [CrossRef] [PubMed]

71. Liao, T.L.; Tseng, C.R.; Yu, C.L.; Wang, Y.P.; Kao, S.H. Estrogen receptor-alpha interacts with mitochondrial protein HADHB and affects beta-oxidation activity. *Mol. Cell. Proteom.* 2012, 11. [CrossRef] [PubMed]

72. Zhou, Z.; Zhou, J.; Du, Y. Estrogen receptor alpha interacts with mitochondrial protein HADHB and affects beta-oxidation activity. *Mol. Cell. Proteom.* 2012, 11. [CrossRef] [PubMed]

73. Simpkins, J.W.; Singh, M.; Brock, C.; Etgen, A.M. Neuroprotection and estrogen receptors. *Neuroendocrinology* 2012, 96, 119–130. [CrossRef] [PubMed]

74. Yang, L.C.; Zhang, Q.G.; Zhou, C.F.; Yang, F.; Zhang, Y.D.; Wang, R.M.; Brann, D.W. Extranuclear estrogen receptors mediate the neuroprotective effects of estrogen in the rat hippocampus. *PLoS ONE* 2010, 5, e9851. [CrossRef] [PubMed]

75. Smith, J.A.; Zhang, R.; Varma, A.K.; Das, A.; Ray, S.K.; Banik, N.L. Estrogen partially down-regulates PTEN in breast cancer susceptibility gene 1-defective breast cancer cells. *Mol. Carcinog.* 2013, 52, 667–675. [CrossRef] [PubMed]

76. Choi, Y.C.; Lee, J.H.; Hong, K.W.; Lee, K.S. 17 Beta-estradiol prevents focal cerebral ischemic brain damage following transient focal cerebral ischemia in rats. *Brain Res.* 2013, 1519, 95–104. [CrossRef] [PubMed]

77. Li, Y.; He, L.; Zeng, N.; Sahu, D.; Cadenas, E.; Shearn, C.; Li, W.; Stiles, B.L. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling regulates mitochondrial biogenesis and respiration via estrogen-related receptor alpha (ERRa). *J. Biol. Chem.* 2013, 288, 25007–25024. [CrossRef] [PubMed]

78. Rodriguez-Cuenca, S.; Monjo, M.; Gianotti, M.; Proenza, A.M.; Roca, P. Expression of mitochondrial biogenesis-signaling factors in brown adipocytes is influenced specifically by 17beta-estradiol, testosterone, and progesterone. *Am. J. Physiol. Endocrinol. Metab.* 2007, 292, E340–E346. [CrossRef] [PubMed]

79. Dillon, L.M.; Miller, T.W. Therapeutic targeting of cancers with loss of PTEN function. *Curr. Drug Targets* 2014, 15, 65–79. [CrossRef] [PubMed]

80. Coppedé, F. Genetics and epigenetics of Parkinson’s disease. *Sci. World J.* 2012, 2012, 489830. [CrossRef] [PubMed]

81. Sushma, P.S.; Jamil, K.; Kumar, P.U.; Satyanarayana, U.; Ramakrishna, M.; Triveni, B. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): A study on south Indian population. *Tumour Biol.* 2016, 37, 7625–7632. [CrossRef] [PubMed]

82. Ueda, M.; Inaba, T.; Nito, C.; Kamiya, N.; Katayama, Y. Therapeutic impact of eicosapentaenoic acid on ischemic brain damage following transient focal cerebral ischemia in rats. *Brain Res.* 2013, 1519, 95–104. [CrossRef] [PubMed]
83. Montgomery, P.; Burton, J.R.; Sewell, R.P.; Spreckelsen, T.F.; Richardson, A.J. Low blood long chain omega-3 fatty acids in UK children are associated with poor cognitive performance and behavior: a cross-sectional analysis from the DOLAB study. *PloS ONE* 2013, **8**, e66697. [CrossRef]  
84. Carey, A.N.; Fisher, D.R.; Joseph, J.A.; Shukitt-Hale, B. The ability of walnut extract and fatty acids to protect against the deleterious effects of oxidative stress and inflammation in hippocampal cells. *Nutr. Neurosci.* 2013, **16**, 13–20. [CrossRef] [PubMed]  
85. Mujahid, M.S.; Janz, N.K.; Hawley, S.T.; Griggs, J.J.; Hamilton, A.S.; Katz, S.J. The impact of sociodemographic, treatment, and work support on missed work after breast cancer diagnosis. *Breast Cancer Res. Treat.* 2010, **119**, 213–220. [CrossRef] [PubMed]  
86. Hoppe, J.B.; Haag, M.; Whalley, B.J.; Salbego, C.G.; Cimarosti, H. Curcumin protects organotypic hippocampal slice cultures from Aβ1–42-induced synaptic toxicity. *Toxicol. Vitr.* 2013, **27**, 2325–2330. [CrossRef] [PubMed]  
87. Cheng, Y.F.; Guo, L.; Xie, Y.S.; Liu, Y.S.; Zhang, J.; Wu, Q.W.; Li, J.M. Curcumin rescues aging-related loss of hippocampal synapse input specificity of long term potentiation in mice. *Neurochem. Res.* 2013, **38**, 98–107. [CrossRef] [PubMed]  
88. Doggui, S.; Belkacemi, A.; Paka, G.D.; Perrotte, M.; Pi, R.; Ramassamy, C. Curcumin protects neuronal-like cells against acrolein by restoring Akt and redox signaling pathways. *Mol. Nutr. Food Res.* 2013, **57**, 1660–1670. [CrossRef] [PubMed]  
89. Wu, J.; Li, Q.; Wang, X.; Yu, S.; Li, L.; Wu, X.; Chen, Y.; Zhao, J.; Zhao, Y.N. Europrotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway. *PloS ONE* 2013, **8**, e59843. [CrossRef] [PubMed]  
90. Li, S.; Pu, X.P. Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson’s disease. *Biol. Pharm. Bull.* 2011, **34**, 1291–1296. [CrossRef] [PubMed]  
91. Yoshida, H.; Okumura, N.; Kitagishi, Y.; Nishimura, Y.; Matsuda, S. Ethanol extract of Rosemary repressed PTEN expression in K562 culture cells. *Int. J. Appl. Biol. Pharm. Technol.* 2011, **2**, 316–322. [PubMed]  
92. Li, J.; Jiang, K.; Zhao, F. Icariin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2. *Oncol. Rep.* 2015, **33**, 2829–2836. [CrossRef] [PubMed]  
93. Xu, B.; Jiang, C.; Han, H.; Liu, H.; Tang, M.; Liu, L.; Ji, W.; Lu, X.; Yang, X.; Zhang, Y.; et al. Icaritin inhibits the invasion and epithelial-to-mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/Akt/HIF-1α signalling. *Clin. Exp. Pharmacol. Physiol.* 2015, **42**, 1296–1307. [CrossRef] [PubMed]  
94. Ito, T.; Pastukh, V.; Solodushko, V.; Azuma, J.; Schaffer, S.W. Effect of taurine on protein kinase C isoforms: role in taurine’s actions? *Adv. Exp. Med. Biol.* 2009, **643**, 3–11. [PubMed]  
95. Cappelli, A.P.; Zoppi, C.C.; Barbosa-Sampaio, H.C.; Costa, J.M., Jr.; Protzek, A.O.; Morato, P.N.; Boscher, A.C.; Carneiro, E.M. Taurine-induced insulin signalling improvement of obese malnourished mice is associated with redox balance and protein phosphatases activity modulation. *Liver Int.* 2014, **34**, 771–783. [CrossRef] [PubMed]  
96. Hu, Z.; Wang, H.; Lee, I.H.; Modi, S.; Wang, X.; Du, J.; Mitch, W.E. PTEN inhibition improves muscle regeneration in mice fed a high-fat diet. *Diabetes* 2010, **59**, 1312–1320. [CrossRef] [PubMed]  
97. Liu, H.; Zang, C.; Emde, A.; Planas-Silva, M.D.; Rosche, M.; Kühnl, A.; Schulz, C.O.; Elstner, E.; Possinger, K.; Eucker, J. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. *Eur. J. Pharmacol.* 2008, **591**, 43–51. [CrossRef] [PubMed]  
98. Dave, B.; Eason, R.R.; Till, S.R.; Geng, Y.; Velarde, M.C.; Badger, T.M.; Simmen, R.C. The soy isoflavone genistein promotes apoptosis in mammary epithelial cells by inducing the tumor suppressor PTEN. *Carcinogenesis* 2005, **26**, 1793–1803. [CrossRef] [PubMed]  
99. Liu, Y.L.; Zhang, G.Q.; Yang, Y.; Zhang, C.Y.; Fu, R.X.; Yang, Y.M. Genistein induces G2/M arrest in gastric cancer cells by increasing the tumor suppressor PTEN expression. *Nutr. Cancer* 2013, **65**, 1034–1041. [CrossRef] [PubMed]
101. Wu, X.; Zhu, Y.; Yan, H.; Liu, B.; Li, Y.; Zhou, Q.; Xu, K. Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells. *BMC Cancer* **2010**, *10*, 269. [CrossRef] [PubMed]

102. Li, W.X.; Chen, L.P.; Sun, M.Y.; Li, J.T.; Liu, H.Z.; Zhu, W. 3’3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling. *Oncotarget* **2015**, *6*, 23776–23792. [CrossRef] [PubMed]

103. Yamamoto, R.; Shimamoto, K.; Ishii, Y.; Kimura, M.; Fujii, Y.; Morita, R.; Suzuki, K.; Shibutani, M.; Mitsumori, K. Involvement of PTEN/Akt signaling and oxidative stress on indole-3-carbinol (I3C)-induced hepatocarcinogenesis in rats. *Exp. Toxicol. Pathol.* **2013**, *65*, 845–852. [CrossRef] [PubMed]

104. Penedo, L.A.; Oliveira-Silva, P.; Gonzalez, E.M.; Maciel, R.; Jurgilas, P.B.; Melibeu, Ada, C.; Campello-Costa, P.; Serfaty, C.A. Nutritional tryptophan restriction impairs plasticity of retinotectal axons during the critical period. *Exp. Neurol.* **2009**, *217*, 108–115. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).